Understanding the role of tubulin
post-translational modification
and mitochondrial impairment in
bortezomib-induced peripheral neurotoxicity
(Cariplo grant agreement No 2019-1482)
Peripheral neuropathy, anti-tubulins, proteasoma inhibitors, cancer,microtubules
UNDERSTAND CIPN, FIGHT CIPN
-
Pathogenic role of delta 2 tubulin in bortezomib-induced peripheral neuropathy
The pathogenesis of chemotherapy-induced peripheral neuropathy (CIPN) is poorly understood.
377000
NEW CASES
In ITALY CANCER INCIDENCE OF CANCER PATIENTS in 2020
3700000
NEW CASES
In EUROPE CANCER INCIDENCE OF CANCER PATIENTS in 2020
7
per 100,000
ANNUAL INCIDENCE OF MULTIPLE MYELOMA IN US
68.1
CIPN prevalence when measured in the first month after chemotherapy
33.33
Can expect to have chronic CIPN 6 months or more after the end of chemotherapy
Estimated incidence
of multiple myeloma
(patient per 100,000 in EUROPE) Bortezomib causes a sensory-predominant axonal peripheral neuropathy in approximately 30% of patients
Comparison by sex
- Female
- Male
- Female
- Male